Plant Name: Millettia pachycarpa
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 6.945E-14 | 5.041E-10 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 6.890E-14 | 5.041E-10 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, PTGS1, PTGS2 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.372E-12 | 4.085E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.576E-12 | 1.104E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 6.150E-12 | 1.116E-08 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.023E-10 | 2.753E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.264E-09 | 2.347E-06 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.374E-09 | 3.062E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.597E-09 | 3.133E-06 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 2.108E-08 | 1.530E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, PTGS1, PTGS2, RAB9A |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.240E-07 | 7.498E-05 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 7.290E-07 | 3.780E-04 | PTGS1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 9.919E-07 | 5.023E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 2.186E-06 | 1.051E-03 | CYP1A1, CYP3A4 |
| CC | GO:0016020; membrane | GO:0031090; organelle membrane | 2.269E-06 | 1.051E-03 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, LMNA, NPC1, PTGS1, PTGS2, RAB9A |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 4.370E-06 | 1.942E-03 | CYP1A1, CYP1A2 |
| CC | GO:0043226; organelle | GO:0043231; intracellular membrane-bounded organelle | 5.296E-06 | 2.307E-03 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, LMNA, NFKB1, NPC1, PKM, PTGS1, PTGS2, PTPN1, RAB9A, SMN1, SMN2 |
| BP | GO:0008152; metabolic process | GO:0072330; monocarboxylic acid biosynthetic process | 7.288E-06 | 3.052E-03 | CYP1A1, PKM, PTGS1, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 7.279E-06 | 3.052E-03 | CYP1A1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 9.956E-06 | 4.090E-03 | CYP1A1, CYP1B1, NFKB1, NPC1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.091E-05 | 4.401E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 1.527E-05 | 5.938E-03 | CYP1A2, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0070887; cellular response to chemical stimulus | 1.581E-05 | 6.041E-03 | CYP1A1, CYP1A2, CYP1B1, LMNA, NFKB1, NPC1, PKM, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 2.035E-05 | 7.511E-03 | CYP1A1, CYP1A2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.820E-13 | 2.510E-11 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 3.370E-09 | 1.500E-07 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 8.372E-09 | 2.484E-07 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.933E-07 | 3.440E-06 | CYP2C9; CYP2C19; PTGS2; PTGS1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.473E-07 | 3.278E-06 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.342E-07 | 3.474E-06 | CYP2C9; CYP1A2; CYP1A1; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.984E-07 | 3.795E-06 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.115E-06 | 3.081E-05 | CYP2C9; PKM; CYP1A2; CYP1A1; PTGS2; CYP2C19; CYP3A4; PTGS1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.097E-06 | 2.332E-05 | CYP2C9; CYP2C19; PTGS2; PTGS1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 4.943E-06 | 4.399E-05 | CYP1A2; CYP1A1; CYP1B1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 9.754E-06 | 7.892E-05 | CYP1A1; CYP1B1; PTGS2 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.019E-03 | 7.560E-03 | PTGS2; PTGS1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.889E-03 | 1.201E-02 | CYP1B1; PTGS2; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.725E-03 | 1.181E-02 | PTGS2; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 2.383E-03 | 1.414E-02 | PTGS2; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 3.863E-03 | 1.910E-02 | PTGS2; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 3.794E-03 | 1.910E-02 | PTPN1; NFKB1 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 2.780E-03 | 1.546E-02 | PTGS2; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 6.176E-03 | 2.618E-02 | LMNA; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 5.839E-03 | 2.598E-02 | RAB9A; NFKB1 |
| hsa03013 | RNA transport_Homo sapiens_hsa03013 | 9.187E-03 | 3.717E-02 | SMN2; SMN1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.285E-02 | 4.972E-02 | PKM; NFKB1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 4.243E-03 | 1.988E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS1; PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | PTGS2; NFKB1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; PTGS2; PTGS2; PTGS2 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; PTGS2; NFKB1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | PKM |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1; PTGS2; PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; PTGS2; PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; PKM |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1 |